About BiBB

BiBBInstruments started in 2013 and operates in the multi-billion market for endoscopic equipment. Dr. Charles Walther, a cancer researcher at Lund University and a senior physician at the Clinical Pathology Department at Skåne University Hospital in Lund founded the company.

BiBBInstruments is developing a series of disposable biopsy instruments, EndoDrill®, with an innovative drilling function that enables earlier and more accurate cancer diagnosis, especially in deeply situated tumors. The planned product portfolio includes six disposable instruments based on the patented EndoDrill®technology and a novel biopsy method still under development. The instruments will be used for tissue sampling (biopsy) of the most common types of cancer, for example; lung, breast, colorectal, prostate and stomach cancer. In the stomach, the lungs and in the small and large bowel, tumors often grow deep underneath the surface and may therefore be hard to sample. The EndoDrill® method provides deeper and representative solid tissue samples compared to other techniques. BiBBInstrument’s first product EndoDrill® GI Upper was successfully evaluated in a randomized clinical trial in Lund and launched in August 2017.

A biopsy is a tissue-sample taken from a tumor suspicious lesion to verify or rule out cancer. Via flexible endoscopes (tube-like camera instruments) tissue-samples are taken for microscopic examination. Many millions of biopsies are taken annually to diagnose the most common types of cancers. Endoscopic examinations including biopsies are expected to continue to increase1 in number as the requirements for early diagnosis grow and endoscopy is a relatively patient friendly and cost effective method. Traditional biopsy instruments, such as needles and forceps, have problems providing fully diagnostic material from deep and difficultly sampled tumors. This in combination with new targeted therapies that demand larger tissue samples to enable refined diagnosis for optimal prognosis and treatment further emphasizes the need for better biopsies. There is consequently a growing clinical need for new biopsy instruments for earlier and safer diagnosis.

References: 1. Frost & Sullivan 2014